BG64679B1 - Амино-терминално скъсени мср-2 като антагонисти на хемокини - Google Patents

Амино-терминално скъсени мср-2 като антагонисти на хемокини Download PDF

Info

Publication number
BG64679B1
BG64679B1 BG104266A BG10426600A BG64679B1 BG 64679 B1 BG64679 B1 BG 64679B1 BG 104266 A BG104266 A BG 104266A BG 10426600 A BG10426600 A BG 10426600A BG 64679 B1 BG64679 B1 BG 64679B1
Authority
BG
Bulgaria
Prior art keywords
mcp
amino
cells
terminally truncated
chemokine
Prior art date
Application number
BG104266A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG104266A (en
Inventor
Paul Proost
Sofie Struyf
Damme Jo Van
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64679(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of BG104266A publication Critical patent/BG104266A/xx
Publication of BG64679B1 publication Critical patent/BG64679B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BG104266A 1997-09-29 2000-03-22 Амино-терминално скъсени мср-2 като антагонисти на хемокини BG64679B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (en) 1997-09-29 1997-09-29 Amino-terminal truncated c-c chemokines as chemokine antagonist
EP97122471A EP0905240A1 (en) 1997-09-29 1997-12-19 Amino-terminally truncated c-c chemokines as chemokine antagonists
EP98104216A EP0905241A1 (en) 1997-09-29 1998-03-10 Amino-terminally truncated c-c chemokines as chemokine antagonists

Publications (2)

Publication Number Publication Date
BG104266A BG104266A (en) 2000-11-30
BG64679B1 true BG64679B1 (bg) 2005-11-30

Family

ID=8227408

Family Applications (2)

Application Number Title Priority Date Filing Date
BG104267A BG64757B1 (bg) 1997-09-29 2000-03-22 Аминотерминално скъсени rаnтеs като хемокинови антагонисти
BG104266A BG64679B1 (bg) 1997-09-29 2000-03-22 Амино-терминално скъсени мср-2 като антагонисти на хемокини

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG104267A BG64757B1 (bg) 1997-09-29 2000-03-22 Аминотерминално скъсени rаnтеs като хемокинови антагонисти

Country Status (29)

Country Link
US (5) US6977071B2 (sk)
EP (6) EP0906954A1 (sk)
JP (2) JP4233214B2 (sk)
KR (2) KR100542934B1 (sk)
CN (3) CN1233415C (sk)
AR (2) AR013529A1 (sk)
AT (3) ATE263242T1 (sk)
AU (2) AU750341B2 (sk)
BG (2) BG64757B1 (sk)
BR (2) BR9812565A (sk)
CA (2) CA2304827A1 (sk)
CY (1) CY1110927T1 (sk)
CZ (2) CZ299478B6 (sk)
DE (3) DE69838188T2 (sk)
DK (3) DK1439231T3 (sk)
EA (2) EA003940B1 (sk)
EE (2) EE200000151A (sk)
ES (3) ES2218860T3 (sk)
HK (3) HK1062637A1 (sk)
HU (2) HU226468B1 (sk)
IL (2) IL135352A (sk)
NO (2) NO20001584D0 (sk)
NZ (3) NZ503235A (sk)
PL (2) PL197569B1 (sk)
PT (3) PT1019507E (sk)
SK (2) SK286439B6 (sk)
UA (2) UA73080C2 (sk)
WO (2) WO1999016876A1 (sk)
ZA (2) ZA988675B (sk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6534626B1 (en) * 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
CA2387378A1 (en) * 1999-10-25 2001-05-03 Euroscreen S.A. Processed human chemokines phc-1 and phc-2
EP1167527A1 (en) * 2000-06-22 2002-01-02 Euroscreen S.A. Processed human chemokines PHC-1 and PHC-2
AU2505601A (en) * 1999-11-15 2001-05-30 Wolf-Georg Forssmann Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
EP1458756B1 (en) 2001-12-17 2009-01-28 Laboratoires Serono SA Chemokine mutants acting as chemokine antagonists
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
DK2185719T3 (en) 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2011097567A1 (en) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity
WO2011112915A2 (en) 2010-03-11 2011-09-15 Health Research, Inc. Methods and compositions containing fc fusiong proteins for enhancing immune responses
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US6159711A (en) * 1994-12-08 2000-12-12 Glaxo Group Limited DNA encoding rantes peptide fragments and methods of treatment with the fragments
AU1532697A (en) * 1996-01-12 1997-08-01 Genetics Institute Inc. Beta-chemokine, h1305 (mcp-2)
CA2250576A1 (en) * 1996-03-27 1997-10-02 Icos Corporation Monocyte chemotactic protein-5 materials and methods
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Baggiolini M. etal, Ann.Rev.Immunol., 55, 97-179, 1994 *

Also Published As

Publication number Publication date
ES2218860T3 (es) 2004-11-16
KR20010024213A (ko) 2001-03-26
NO20001584L (no) 2000-03-27
DK1439231T3 (da) 2007-11-05
CN1148447C (zh) 2004-05-05
HUP0003563A2 (hu) 2001-02-28
EP1019507A1 (en) 2000-07-19
ES2287601T3 (es) 2007-12-16
CN1145693C (zh) 2004-04-14
US20030119148A1 (en) 2003-06-26
SK286439B6 (sk) 2008-10-07
US20030124677A1 (en) 2003-07-03
ES2215324T3 (es) 2004-10-01
HUP0003505A3 (en) 2005-11-28
WO1999016876A1 (en) 1999-04-08
ZA988675B (en) 1999-11-24
EP1021541B1 (en) 2004-04-14
HU226414B1 (en) 2008-11-28
EE200000152A (et) 2001-02-15
KR100542934B1 (ko) 2006-01-11
JP2001518296A (ja) 2001-10-16
HUP0003563A3 (en) 2005-11-28
NZ503235A (en) 2002-08-28
BR9812394A (pt) 2000-09-12
ATE368742T1 (de) 2007-08-15
SK4502000A3 (en) 2000-09-12
IL135351A (en) 2006-08-20
NO20001584D0 (no) 2000-03-27
KR100560275B1 (ko) 2006-03-10
DE69823218D1 (de) 2004-05-19
NZ516027A (en) 2003-05-30
PT1439231E (pt) 2007-08-20
US6905676B2 (en) 2005-06-14
NZ503234A (en) 2002-06-28
CN1233415C (zh) 2005-12-28
WO1999016877A1 (en) 1999-04-08
CZ20001146A3 (cs) 2000-09-13
EP0905241A1 (en) 1999-03-31
CA2305017A1 (en) 1999-04-08
DE69838188D1 (de) 2007-09-13
US20050164936A1 (en) 2005-07-28
BR9812565A (pt) 2000-08-01
PL339545A1 (en) 2000-12-18
ATE263242T1 (de) 2004-04-15
NO20001609D0 (no) 2000-03-28
EE200000151A (et) 2001-02-15
BG104267A (en) 2000-11-30
AR013528A1 (es) 2000-12-27
AU9747498A (en) 1999-04-23
EP1021541A1 (en) 2000-07-26
AU750341B2 (en) 2002-07-18
BG64757B1 (bg) 2006-02-28
SK286495B6 (sk) 2008-11-06
ATE264390T1 (de) 2004-04-15
EP1019507B1 (en) 2004-03-31
CA2304827A1 (en) 1999-04-08
HU226468B1 (en) 2008-12-29
HK1062637A1 (en) 2004-11-19
NO20001609L (no) 2000-03-28
PL197569B1 (pl) 2008-04-30
AU9442098A (en) 1999-04-23
EP1439231A3 (en) 2004-12-22
AU750606B2 (en) 2002-07-25
SK4512000A3 (en) 2000-09-12
CY1110927T1 (el) 2015-06-10
JP2001518297A (ja) 2001-10-16
US6977071B2 (en) 2005-12-20
EP1439231A2 (en) 2004-07-21
EP0905240A1 (en) 1999-03-31
EP1439231B1 (en) 2007-08-01
JP4233214B2 (ja) 2009-03-04
JP4230659B2 (ja) 2009-02-25
CZ299478B6 (cs) 2008-08-06
DE69823218T2 (de) 2004-08-26
EP0906954A1 (en) 1999-04-07
CZ299479B6 (cs) 2008-08-06
EA200000379A1 (ru) 2000-10-30
CN1490049A (zh) 2004-04-21
DE69822856T2 (de) 2004-08-19
PL196427B1 (pl) 2008-01-31
PT1019507E (pt) 2004-06-30
EA003942B1 (ru) 2003-10-30
AR013529A1 (es) 2000-12-27
DK1021541T3 (da) 2004-08-02
HK1032426A1 (en) 2001-07-20
ZA988676B (en) 1999-12-03
DE69838188T2 (de) 2007-11-22
PL339559A1 (en) 2000-12-18
HUP0003505A2 (hu) 2001-02-28
CN1271386A (zh) 2000-10-25
DK1019507T3 (da) 2004-07-19
DE69822856D1 (de) 2004-05-06
PT1021541E (pt) 2004-07-30
IL135352A (en) 2006-08-20
HK1032425A1 (en) 2001-07-20
EA200000378A1 (ru) 2000-10-30
EA003940B1 (ru) 2003-10-30
CN1271385A (zh) 2000-10-25
US7326411B2 (en) 2008-02-05
UA73080C2 (en) 2005-06-15
US7338653B2 (en) 2008-03-04
US20050201977A1 (en) 2005-09-15
UA73081C2 (en) 2005-06-15
CZ20001147A3 (cs) 2000-09-13
US20050220790A1 (en) 2005-10-06
BG104266A (en) 2000-11-30
KR20010024214A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
US7338653B2 (en) Amino-terminally truncated MCP-2 as chemokine antagonists
MXPA00002880A (en) Amino-terminally truncated mcp-2 as chemokine antagonists